SBIR Phase II: A computational and experimental platform for the automated design of organisms used in the production of biochemicals

Information

  • NSF Award
  • 1456372
Owner
  • Award Id
    1456372
  • Award Effective Date
    3/1/2015 - 10 years ago
  • Award Expiration Date
    2/28/2017 - 8 years ago
  • Award Amount
    $ 760,814.00
  • Award Instrument
    Standard Grant

SBIR Phase II: A computational and experimental platform for the automated design of organisms used in the production of biochemicals

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to develop a platform to rapidly design synthetic organisms to produce biochemicals, which will replace environmentally harmful, ecologically inefficient industrial chemical processes. The technology developed in this proposal will provide a competitive edge in the rapid engineering of synthetic organisms to produce biochemicals by fermentation that are currently produced from oil (reducing our CO2 emissions) or extracted from natural species (reducing our taxing load on existing ecosystems). This technology also has the potential to be used for the manufacture of drugs, and to engineer novel organisms to improve crop production and therefore help address the mounting challenges of providing food to a growing world population without tapping too much in Earth's resources. Commercially, the chemicals that will be enabled by application of the technology developed during the Phase I program open up billion dollar markets that are currently inaccessible to the chemical industry. <br/><br/>This SBIR Phase II project proposes to develop a platform that combines computational enzyme design with systems biology to create a fully integrated system for the design and testing of novel cell factories for the production of bulk and fine chemicals. During the Phase I project, the company, in collaboration with the University of Washington, has successfully developed a high-performance software code to rapidly design novel metabolic pathways to produce any target chemical from central metabolism. In Phase II, the company will further advance the concept by (1) developing a high-performance pathway prioritization module to estimate each designed pathway yield and impact on organism metabolism in the context of whole-genome models and (2) use the software platform to design libraries of pathways for the production of a variety of specialty chemical targets that are commercially valuable and not known to be produced by fermentation at scale. Then, (3) using an experimental screening setup, the DNA for all the proposed pathways will be assembled screened at high-throughput for detectable production of the target chemicals.

  • Program Officer
    Ruth M. Shuman
  • Min Amd Letter Date
    2/18/2015 - 10 years ago
  • Max Amd Letter Date
    7/18/2016 - 9 years ago
  • ARRA Amount

Institutions

  • Name
    ARZEDA Corp.
  • City
    Seattle
  • State
    WA
  • Country
    United States
  • Address
    2715 W Fort St
  • Postal Code
    981991224
  • Phone Number
    2064026506

Investigators

  • First Name
    Alexandre
  • Last Name
    Zanghellini
  • Email Address
    alexandre.zanghellini@arzeda.com
  • Start Date
    2/18/2015 12:00:00 AM

Program Element

  • Text
    SMALL BUSINESS PHASE II
  • Code
    5373

Program Reference

  • Text
    SMALL BUSINESS PHASE II
  • Code
    5373
  • Text
    Biotechnology
  • Code
    8038
  • Text
    RESEARCH EXP FOR UNDERGRADS
  • Text
    SUPPL FOR UNDERGRAD RES ASSIST
  • Code
    9231
  • Text
    RES EXPER FOR UNDERGRAD-SUPPLT
  • Code
    9251